Biotech & Pharmaceuticals

The track record in drug development for Alzheimer’s disease has been terrible: a success rate of less than 1 percent.

Almost 200,000 people have fatally overdosed on opioids in the past 15 years, with more than 30,000 people dying in 2015 alone.

Traders are worried that Repatha isn’t effective enough to justify the drug’s hefty price tag of over $14,500 per year.

The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer.

Express Scripts said despite the double-digit increase, costs for employers rose just 2.5 percent across all prescription drugs.

More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.

Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one’s more frustrated than her.

With biotech stocks at their highest level since January, one strategist thinks a Donald Trump presidential win could send them even higher.

Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.

Meg Tirrell explains what to look for in the biotech industry in 2016.

One morning in October, I was frantically scrambling around my apartment, trying to find a thumb drive. It’s probably the most valuable thumb drive I’ll ever have, and I couldn’t believe I had misplaced it. It contains the blueprint of who I am: My genome. Or at least, all the ways my genes differ from …

Meg Tirrell reports from the American Society of Hematology’s annual meeting where many of the latest blood disease treatments were presented.

There may be a big advantage to treating people with personalized medicine — drugs and treatments tailored to an individual’s genetic profile — but improved health outcomes for them will come at a big cost. That’s because it is very costly to screen patients for such tailored treatments and to produce medicine that targets individuals …

Of the 41 new drugs that were FDA-approved in 2014, 18 were for drugs with orphan indications, a record level.

Pfizer and Allergan are combining in a $160 billion deal, handing Pfizer a new address and creating a lot of controversy.